Marker Therapeutics (MRKR) Assets Average (2011 - 2026)

Marker Therapeutics (MRKR) has 16 years of Assets Average data on file, last reported at $18.3 million in Q1 2026.

• Assets Average for Q1 2026 came in at $18.3 million, down 6.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.3 million (down 6.44% YoY), and the FY2025 annual result was $20.5 million, up 4.96% from the prior year.
• Assets Average fell to $18.3 million in Q1 2026 per MRKR's latest filing, from $20.4 million in the prior quarter.
• Over five years, Assets Average peaked at $61.5 million in Q1 2022 and troughed at $11.3 million in Q3 2024.
• A 5-year average of $26.1 million and a median of $19.5 million in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2025: Assets Average sank 55.65% in 2023, then soared 61.62% in 2025.
• A 5-year view of Assets Average shows it stood at $37.8 million in 2022, then sank by 51.53% to $18.3 million in 2023, then retreated by 10.05% to $16.5 million in 2024, then grew by 23.9% to $20.4 million in 2025, then fell by 10.54% to $18.3 million in 2026.
• Business Quant data shows MRKR's Assets Average at $18.3 million in Q1 2026, $20.4 million in Q4 2025, and $18.3 million in Q3 2025.